Oncology

Priority review status will allow for expedited development of zongertinib, putting it on the path toward approval as the first in a new class of drugs for mutated NSCLC.

The 75 minutes of infusion time typically required is costly and difficult for patients.

T-DXd has a boxed warning for interstitial lung disease and pneumonitis.

Using new treatment advances, traditional medications, genetic profiles, immunotherapies, and individualized plans enables providers to improve outcomes for patients with TPBC.

The test offers an accurate, fast, low-cost, and noninvasive tool for early diagnosis of pancreatic ductal adenocarcinoma.

Treatment selection includes patient factors, cost, adverse effects, and drug interactions.

Second-line and later treatment options for small cell lung cancer are limited.

Nivolumab demonstrated a sustained disease-free survival benefit over placebo in high-risk muscle-invasive urothelial carcinoma (MIUC).

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium.

DLL3 is an emerging therapeutic target in small cell lung cancer and other neuroendocrine carcinomas, with 1 FDA-approved therapy and several others under investigation.

C. Brooke Adams, PharmD, BCOP, discusses the evolving diagnostic criteria and management strategies for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapy, highlighting advances in toxicity prevention and treatment selection.

Data from the phase 2 CABRAMET trial suggests the potential of cabozantinib for treatment of brain metastases from renal cell carcinoma (RCC).

Enfortumab vedotin, trastuzumab deruxtecan, and disitamab vedotin were highlighted at the 2025 ASCO Genitourinary Cancers Symposium.

Panelists at the 2025 ASCO Genitourinary Cancers Symposium discussed challenges and new approaches to treatment.

The indication is for symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.

The combination of the antibody-drug conjugate and PD-1/L1 inhibitor yielded an improved progression-free survival in locally advanced or metastatic urothelial carcinoma.

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California.

The cancer cells developed their own electrical network similar to neural behavior seen in the brain.

The expanding role of real-world evidence in regulatory and health technology assessment (HTA) decision-making highlights its growing acceptance for supplementing clinical trial data, addressing evidence gaps, and informing treatment value, despite challenges in data quality, accessibility, and regulatory compliance.

Andrew Lin, PharmD, BCOP, discusses his pharmacist-led study examining the association between early tacrolimus levels and outcomes post-allogeneic hematopoietic cell transplantation.

The combination greatly improved progression-free survival and overall survival.

Talazoparib in combination with enzalutamide yielded significant improvements in radiographic progression-free survival and overall survival.

Currently, the Cadherin-6 targeting antibody-drug conjugate is undergoing evaluation in a phase 1a/1b clinical trial.

Building on a previously granted orphan drug designation, the latest FDA action for amezalpat puts the drug in a position for regulatory approval.

Up to 61% of all non-small cell lung cancer (NSCLC) cases harbor EGFR mutations.

Black women have higher rates of triple-negative breast cancer (TNBC) incidence and mortality than the general US population. Despite this, they are underrepresented in TNBC clinical trials.

Diversity in clinical trials remains important to ensure research data for therapies accurately reflects the diverse patient populations who will use them globally.

The approval follows the ECHELON-3 study, which enrolled adults with relapsed or refractory large B-cell lymphoma.